罗氟司特功效与作用

Roflumilast is a long-acting inhibitor of selective phosphodiesterase type 4 (PDE-4) and has anti-inflammatory effects. Phosphodiesterases are a family of enzymes including at least 11 subtypes of enzymes that catalyze the decomposition of the messenger molecules cyclic adenosine monophosphate and/or cyclic guanosine monophosphate. Phosphodiesterase-4 is a major cyclic adenosine monophosphate metabolic enzyme in inflammatory and immune cells, and phosphodiesterase-4 inhibitors have broad anti-inflammatory activities including inhibiting the release of inflammatory mediators and inhibiting immune cell activation. In addition, phosphodiesterase-4 inhibitors have also been shown to have therapeutic effects in animal models of airway inflammation. The British National Institute for Health and Clinical Excellence (NICE) recommended roflumilast for the treatment of severe chronic obstructive pulmonary disease COPD as early as January 2012, and in July 2017 recommended roflumilast for the treatment of all severity chronic obstructive pulmonary disease COPD. This is a full affirmation of the good cost-effectiveness of roflumilast in the treatment of this indication.

Multiple clinical studies have shown that roflumilast can reduce the frequency of acute exacerbations and improve lung function in patients with moderate to severe COPD. The drug has good efficacy in the maintenance treatment of patients with chronic bronchitis-related symptoms, a history of frequent exacerbations, and severe COPD. Roflumilast tablets mainly act on a variety of inflammatory cells and can effectively inhibit the release of inflammatory mediators such as neutrophils, alveolar macrophages, CD8+ T cells and mast cells. It may play an important role in the treatment of COPD, which is characterized by inflammatory response.

Roflumilast film tablets are oral tablets that can be taken once a day and must be combined with other bronchodilators. Roflumilast film tablets are suitable for the maintenance treatment of severe chronic obstructive pulmonary disease COPD (post-diastolic FEV1 less than 50% of the expected value) associated with chronic bronchitis in adult patients with a history of frequent exacerbations.

Treatment with roflumilast will also produce certain side effects or adverse reactions, among which the most common adverse reactions (≥2%) are: diarrhea/weight loss/nausea/headache/back pain/flu/insomnia/dizziness/loss of appetite, etc. Before receiving treatment with roflumilast film tablets, patients should go to the hospital for a detailed examination and strictly follow the doctor's diagnosis and treatment recommendations.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended related articles: